Linden Lalley-Chareczko1, Devon Clark1, Caitlin Conyngham2, Athena Zuppa3, Ganesh Moorthy4, Karam Mounzer1, Helen Koenig1,5. 1. Philadelphia FIGHT Community Health Centers, Philadelphia, PA. 2. AIDS Activities Coordinating Office, Philadelphia Department of Public Health, Philadelphia, PA. 3. Division of Pediatric Critical Care Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA. 4. Division of Clinical Pharmacology & Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA. 5. Division of Infectious Diseases, MacGregor Infectious Diseases Clinic, Hospital of the University of Pennsylvania, Philadelphia, PA.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) for HIV prevention with daily tenofovir and emtricitabine is effective when taken consistently. Currently, there is no objective way to monitor PrEP adherence. Urine has been shown to be highly correlated with plasma tenofovir levels, with urine tenofovir levels >1000 ng/mL demonstrating recent (1-2 days) adherence to PrEP. SETTING: This study was conducted at an urban community health center in Philadelphia, Pennsylvania. METHODS: PrEP was administered to 50 young men who have sex with men and transgender women of color using weekly, biweekly, and/or monthly dispensation schedules. Primary objectives were retention at 48 weeks (in care at week 48 and completing ≥50% of medication pickups) and adherence assessed by urine tenofovir levels. Risk behaviors and sexually transmitted infection diagnoses were also collected. RESULTS: Seventy percent of participants were retained in care at 48 weeks. The proportion of subjects with urine tenofovir consistent with recent adherence was 80, 74.4, 82.4, 82.4, and 69.7% at weeks 4, 12, 24, 36, and 48, respectively. Sixty-one sexually transmitted infections were diagnosed over 231 screenings throughout 48 weeks, with no significant change between the first and second 24-week periods (P = 0.43; 0 seroconversions). At week 48, more than half of subjects reported an increase or no change in condom use, an increase in their ability to discuss HIV with partners, and no change in number of sexual partners from baseline. CONCLUSIONS: These data demonstrate PrEP can be successfully delivered to a high-risk population with high program retention and medication adherence measured by urine tenofovir levels.
BACKGROUND: Pre-exposure prophylaxis (PrEP) for HIV prevention with daily tenofovir and emtricitabine is effective when taken consistently. Currently, there is no objective way to monitor PrEP adherence. Urine has been shown to be highly correlated with plasma tenofovir levels, with urine tenofovir levels >1000 ng/mL demonstrating recent (1-2 days) adherence to PrEP. SETTING: This study was conducted at an urban community health center in Philadelphia, Pennsylvania. METHODS: PrEP was administered to 50 young men who have sex with men and transgender women of color using weekly, biweekly, and/or monthly dispensation schedules. Primary objectives were retention at 48 weeks (in care at week 48 and completing ≥50% of medication pickups) and adherence assessed by urine tenofovir levels. Risk behaviors and sexually transmitted infection diagnoses were also collected. RESULTS: Seventy percent of participants were retained in care at 48 weeks. The proportion of subjects with urine tenofovir consistent with recent adherence was 80, 74.4, 82.4, 82.4, and 69.7% at weeks 4, 12, 24, 36, and 48, respectively. Sixty-one sexually transmitted infections were diagnosed over 231 screenings throughout 48 weeks, with no significant change between the first and second 24-week periods (P = 0.43; 0 seroconversions). At week 48, more than half of subjects reported an increase or no change in condom use, an increase in their ability to discuss HIV with partners, and no change in number of sexual partners from baseline. CONCLUSIONS: These data demonstrate PrEP can be successfully delivered to a high-risk population with high program retention and medication adherence measured by urine tenofovir levels.
Authors: Matthew A Spinelli; David V Glidden; Peter L Anderson; Monica Gandhi; Stephanie Cohen; Eric Vittinghoff; Megan E Coleman; Hyman Scott; Oliver Bacon; Richard Elion; Michael A Kolber; Susan P Buchbinder; Albert Y Liu Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Sarah Wood; Robert Gross; Judy A Shea; José A Bauermeister; Joshua Franklin; Danielle Petsis; Meghan Swyryn; Linden Lalley-Chareczko; Helen C Koenig; Nadia Dowshen Journal: AIDS Behav Date: 2019-10
Authors: Jing Zhang; Chunyan Li; Junjie Xu; Zhili Hu; Sarah E Rutstein; Joseph D Tucker; Jason J Ong; Yongjun Jiang; Wenqing Geng; Sarah T Wright; Myron S Cohen; Hong Shang; Weiming Tang Journal: Lancet HIV Date: 2022-04 Impact factor: 16.070
Authors: Matthew A Spinelli; David V Glidden; Warren C Rodrigues; Guohong Wang; Michael Vincent; Hideaki Okochi; Karen Kuncze; Megha Mehrotra; Patricia Defechereux; Susan P Buchbinder; Robert M Grant; Monica Gandhi Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Monica Gandhi; Peter Bacchetti; Matthew A Spinelli; Hideaki Okochi; Jared M Baeten; Oraphan Siriprakaisil; Virat Klinbuayaem; Warren C Rodrigues; Guohong Wang; Michael Vincent; Tim R Cressey; Paul K Drain Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731